Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study

Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting

“…Our findings confirm those of other studies regarding previous treatment with etanercept does not increase or change the nature of side effects of adalimumab therapy for psoriasis provided the correct patient selection and careful follow-up (8,16,17). None of our patients had to discontinue treatment with etanercept or adalimumab due to side effects.…”

“…We have measured the response comparing the baseline PASI score before the introduction of adalimumab (course baseline) with successive PASI scores during 52 weeks (8). This way to calculate the response has usually been used in several previous reports of short cohorts of patients treated with etanercept and successively until 48 weeks with adalimumab (8,14,16,(26)(27)(28). Ortonne et al in a subanalysis of a 16-week, double-blind, randomized, controlled trial to assess the efficacy and safety of adalimumab for psoriasis found no significant differences in the PASI 75 improvement between patients with and without previous anti-TNF treatment regardless of which prior anti-TNF agent had been used, the number of prior anti-TNFs tried, or reasons for discontinuation of prior anti-TNF therapy (17 (17).…”

“…Adalimumab has been shown to be effective and well-tolerated anti-TNF drug in patients with moderate to severe psoriasis in clinical trials and clinical practice surveys both in continuous therapy and interruption and in retreatment regimens (9)(10)(11)(12). Although long-term loss of response is frequent in psoriasis treated by anti-TNF drugs (7,13) and switching from etanercept to adalimumab is a logic choice in daily practice, there are only some reports on small cohorts of patients and subanalysis of clinical trials in which this switch is evaluated (8,(14)(15)(16)(17). Furthermore, the relationship between the reasons for etanercept failure and the outcome of a further adalimumab therapy in daily practice has only occasionally been analyzed (8).…”

Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab

“…Many patients are managed satisfactorily on adalimumab or etanercept, but some experience loss of effect over time. Recent studies have shown that patients with psoriasis who have failed to achieve an initial response or lost response to etanercept can benefit from adalimumab treatment . Loss of response to adalimumab may be due to antiadalimumab antibodies in some patients.…”

Drug survival rates for tumour necrosis factor-α antagonists in psoriasis

“…Teledermatology has shown its use in war zones 7 and mobile teledermatology in Africa. 8 However, further larger-scale clinical studies with economic assessments demonstrating cost-effectiveness will be needed before mobile teledermatology becomes widely adopted in societies where access to a dermatologist is a fairly straightforward process. The introduction of biologic treatments for inflammatory diseases over the past decade has had a profound impact on the management of these diseases.…”